# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-23-020189
Filing Date
2023-04-25
Accepted
2023-04-25 16:04:57
Documents
6
Period of Report
2023-06-08

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | ny20007681x1_def14a.htm | DEF 14A | 719869
2 |  | ny20007681x1-pc_1.jpg | GRAPHIC | 621638
3 |  | ny20007681x1-pc_2.jpg | GRAPHIC | 455203
4 |  | ny20007681x1_linechart1x2.jpg | GRAPHIC | 90830
5 |  | ny20007681x1_linechart2x2.jpg | GRAPHIC | 86366
6 |  | sig_douglaslovex1.jpg | GRAPHIC | 11471
| Complete submission text file | 0001140361-23-020189.txt |  | 2462674

Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39402 | Film No.: 23844842
SIC: 2834 Pharmaceutical Preparations